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Abstract An extracellular t ipeptidyl aminopeptidase has been purified from Streptomyces lividans 66 cell-free cultures. The enzyme is a major 
component of the secreted proteolytic activity. The protease removes only the N-terminal tripeptide from recombinant human GM-CSF and IL-3 
but does not cleave recombinant human IL-6. The enzyme cleaves the synthetic tripeptide substrates APA-pNA and APM-pNA but does not cleave 
substrates with blocked amino terminals. Smaller substrates are not cleaved. The enzyme appears to be a serine protease of 55 kDa molecular weight. 
The pH optimum is between 7.5 and 8.5 but varies slightly with the substrate. The N-terminal sequence and amino acid composition have been 
determined. 
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1. Introduction 
Recombinant genetic expression systems employing Strepto- 
myces lividans have been used to produce a variety of  recombi- 
nant protein products [1-3]. Soluble biologically active proteins 
are secreted directly into the media thereby eliminating the 
difficulties associated with solubilizing and refolding proteins 
generated as inclusion bodies. These secreted proteins are vul- 
nerable to degradation by extracellular proteases. Analysis of  
human recombinant granulocyte macrophage-colony stimulat- 
ing factor (GM-CSF),  interleukin-3 (IL-3), and erythropoietin 
(EPO) produced by S. lividans 66 revealed the presence of 
degradation products missing the N-terminal tripeptide ( -3  
forms). While the production of extracellular proteases in 
Streptomyces griseus and several other species has been studied 
extensively, few enzymes have been identified in S. lividans 
[4-6]. A chymotrypsin-like activity has been reported in 
S. lividans TK24 and a neutral protease has been reported in 
S. lividans 66 [7-10]. We describe the isolation and characteriza- 
tion of  a major extracellular protease from S. lividans 66. This 
enzyme is a tripeptidyl aminopeptidase (TAP) capable of  re- 
moving the N-terminal tripeptide from both IL-3 and GM-  
CSF. Tripeptidyl peptidases have not been previously reported 
in Streptomyces or other eukaryotic species. 
2. Materials and methods 
2.1. Materials 
GM-CSF and IL-3 were produced by Cangene via expression in 
S. lividans 66. N-AC-APA-pNA, Boc-AP, A-AMC, M-pNA, S-bNA, 
Boc-AAPA-pNA, and SASRIN resins were obtained from Bachem 
Biosciences. A-pNA, R-pNA, L-pNA, P-pNA, AA-pNA, GP-pNA, 
N-Bz-VGR-pNA, and N-Bz-R-pNA were obtained from Sigma. 
D-PFR-pNA was obtained from KabiVitrum (Stockholm, Sweden). 
*Corresponding author: Fax: (1) (905) 673 5123. 
Abbreviations: EPO, recombinant human erythropoeitin; GM-CSF, re- 
combinant human granulocyte macrophage colony stimulating factor; 
IL-3, recombinant human interleukin-3; IL-6, recombinant human 
N-alanyl interleukin-6; PMSF, phenylmethanesulfonylfluoride; TAP, 
tripeptidyl aminopeptidase. 
2.2. Purification of TAP 
S. lividans 66 cells were removed from 11 litres of fermentation broth 
by ultrafiltration with a 0.45 gm filter (Pellicon System, Millipore). 
Proteins in the filtrate were concentrated 20-fold by ultra filtration em- 
ploying a membrane with a 10 kDa cutoff (Millipore). The protease 
activity was followed by assaying with APA-pNA and GM-CSF as 
described below. The protease was precipitated at4°C by lowering the 
pH to 4.0 with 0.1M HC1. The precipitate was collected by centrifuga- 
tion (Model J2-21, Beckman) at 10,000 x g at 4-10°C and was redis- 
solved in 50 ml 10 mM Tris-HCl, pH 8.0. After dialysis against 4 litres 
of 10 mM Tris-HCl, pH 8.0 at 4°C, the protease was loaded at ambient 
temperature onto a 1.6 x 10 cm anion-exchange column (Q-Sepharose 
Fast Flow, Pharmacia) equilibrated with 10 mM Tris-HCl, pH 8.0. 
After washing with equilibration buffer, the bound protease was eluted 
with a 200 ml gradient from 0 to 500 mM NaCI at a flow rate of 
2 ml/minute. The active fractions were pooled and made 2 M in ammo- 
nium sulfate. This material was loaded at ambient temperature onto a 
1.6 x 10 cm hydrophobic interaction column (Phenyl-Sepharose Fast 
Flow, Pharmacia) equilibrated in 10 mM Tris-HCl, pH 8.0, 2 M ammo- 
nium sulfate. After washing with equilibration buffer, the column was 
eluted with a 200 ml gradient from to 2 to 0 M ammonium sulfate at 
a flow rate of 2 ml/min. The active fractions were assayed for purity by 
SDS-PAGE [11]. 
2.3. Assay of TAP with GM-CSF or IL-3 
TAP was assayed by preparing 100-fold ilutions of column fractions 
with 20 mM Tris-HCl, pH 8.0. When GM-CSF was the substrate, 20 
btl of the TAP dilution was added to 10 gl of GM-CSF (10 gg) and 20 
/.d 20 mM Tris-HCl, pH 8.0. The assays were incubated at 37°C for 
2 h. 20gl of 125 mM Tris-HCl, pH 6.8, 0.1% Bromophenol b ue in 50% 
glycerol were added. Products were separated by native gel electropho- 
resis at constant current on a 17% polyacrylamide gel by a modification 
of the method of Davies [12] in which all buffers are pH-adjusted with 
H2SO4 (Fig. 1A). Product identity was initially established by amino 
acid sequencing. 
When IL-3 was the substrate, 10/zl of TAP was added to 50/~1 20 
mM Tris-HCl, pH 8.0 plus 40 gl IL-3 (2.5 gglgl). The assays were 
incubated at 370C. 25 gl aliquots were withdrawn at the desired time 
points and frozen on crushed ry ice. The products were separated by 
isoelectric focusing from pH 3-10 using a Multiphore II electrophoresis 
unit (LKB) and Pharmalyte 3-10 (Pharmacia) ampholytes. Intact IL-3 
has a pI = 7.4. The-  3 form demonstrates a pI = 7.1 (Fig. 1B). Products 
were initially identified by amino acid sequencing. 
2.4. Assay of TAP with synthetic substrates 
When APA-pNA was employed as substrate, the assay was con- 
ducted in a 96-well microtiter plate. 50 gl 100 mM Tris-HC1, pH 8.0, 
were added followed by 25 gl 3.2 mM APA-pNA. 25/tl of TAP were 
added to the wells and the absorbance was read at 405 nm. The assays 
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were incubated at 37°C for 2 h. The absorbance was read at 405 nm 
at time points as needed. The activity (release of p-nitroaniline) was 
calculated from the change in absorbance. 
Fluorescent substrates w re assayed under the same conditions. 
fl-Naphthylamine and 7-amino-4-methylcoumarin release were meas- 
ured using the 400 nm/450 nm excitation/emission block in a Pandex 
Fluorescent Concentration Analyzer (Idexx). 
2.5. Protease inhibition survey 
For inhibitor studies, TAP stock was diluted 100-fold with 20 mM 
Tris-HCl, pH 8.0. The inhibitor was added to the enzyme solution and 
preincubated for 30 min at 22°C. When the preincubation was com- 
plete, the appropriate substrate was dded and the assays were incu- 
bated at 37°C for the desired time period. Products were analyzed as 
described in the respective assays. 
2.6. Protein sequencing 
Purified TAP was adsorbed onto a polyvinylidenedifluoride (PVDF) 
membrane (Immobilon, Millipore) by the method of Matsudaira [13]. 
After visualization with Amido black, the sample was excised and used 
for amino acid analysis andautomated Edman degradation for 15 
cycles. 
2. Z Synthesis of substrates 
APA-pNA, APA-AMC, APM-pNA, and APS-bNA were synthe- 
sized by coupling Boc-AP with A-pNA, A-AMC, M-pNA, andS-bNA, 
respectively, by the mixed anhydride method followed by deblocking 
with trifluoroacetic acid. AAPA-pNA was prepared by deblocking Boc- 
AAPA-pNA with trifluoroacetic acid. N-Carbobenzoxy-APARSPA- 
pNA was synthesized by manual solid phase methods employing a 
SASRIN resin. 
3. Results and discussion 
Sequence analysis of degradation products found during the 
production of human recombinant GM-CSF, IL-3, and EPO 
revealed the proteolytic removal of the N-terminal tripeptide 
sequences (APA-, APM-, and APP- respectively). The synthetic 
substrate, APA p-nitroanilide (APA-pNA), was prepared as an 
analog of the GM-CSF amino terminal and was included in a 
survey of the proteolytic activities present in the cell-free fer- 
mentation broths. 
As seen in Fig. 2, the APA-pNA cleaving activity was the 
major protease found in the survey. The presence of a two step 
cleavage via removal of AP followed by hydrolysis of A-pNA 
was eliminated by the low activities towards AP-pNA and 
A-pNA. The presence of an elastase-like endoproteinase was 
discounted by the lack of measurable cleavage of Boc-AAPA- 
pNA or N-Ac-APA-pNA in the filtrates [14-16]. 
The enzyme was purified as described above. Activity was 
monitored by assaying with both the spectrophotometric APA- 
pNA and the electrophoretic GM-CSF native gel assay (Fig. 
1A). SDS-PAGE (Fig. 3) shows the purification obtained. 
The enzyme demonstrates a molecular weight of 55,000 Da 
on SDS-PAGE. The first 15 residues of the N-terminal 
sequence obtained by automated Edman degradation gave 
the sequence Asp-Gly-His-Gly-His-Gly-Arg-Ser-Trp-Asp-Arg- 
Glu-Ala-Arg-Gly. The amino acid composition (excluding Cys 
and Trp) results are shown in Table 1. 
The cleavage specificity of the pure enzyme was examined 
with both proteins and synthetic substrates. The enzyme readily 
removes the first N-terminal tripeptide from GM-CSF and IL-3 
but fails to cleave IL-6 (possessing an additional N-terminal 
alanine residue). Attempts to force cleavage of IL-6 and further 
cleavage of GM-CSF and IL-3 by increasing the en- 
zyme:substrate ratio by a factor of 1,000 while simul- 
taneously extending the digestion time by a factor of 10 yielded 
no new products. 
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Fig. 1. Resolution fintact and (- 3) degradation products from GM-CSF and IL-3. Proteins were digested and electrophoresed as described in section 
2. (A) Separation of GM-CSF and GM-CSF(- 3) form by native gel electrophoresis. Lane 1, intact GM-CSF; lane 2, mixture of GM-CSF and 
GM-CSF(-3); lane 3, purifed GM-CSF(-3). (B) Separation of IL-3 and IL-3(-3) form by isoelectric focusing. Lane 1, IL-3 + TAP, 4 h; lane 
2, IL-3 + TAP, 2 h; lane 3, IL-3 + TAP, 1 h; lane 4, IL-3 + TAP, 0 h; lane 5, human erythrocyte carbonic anhydrase II (Sigma, pl = 7.4); lane 6, 
pI standards. 
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Fig. 2. Cleavage of synthetic substrates by S. lividans fermentation 
broth. The assays were conducted in50 mM Tris-HCl, pH 8.0 with 0.8 
mM substrate incubated at 37°C. The results are reported as micro- 
moles ofp-nitroaniline r leased in 1 h by1.0 ml of fermentation broth. 
1, APA- pNA; 2, D-PFR-pNA; 3, L-pNA; 4, R-pNA; 5, P-pNA; 
6, AP-pNA; 7, A-pNA; 8, AA-pNA; 9, N-benzoyI-R-pNA; 10, Boc- 
AAPA-pNA; 11, N-acetyl-APA-pNA; 12, N-benzoyl-Y-pNA. 
The protease isactive against APA-pNA and the fluorogenic 
analog APA 7-amido-4-methylcoumarin (APA-AMC). The ki- 
netic constants for cleavage of APA-pNA by TAP are Km = 37 
HM and Vmax = 55 Hmol •min- ~ • mg- t at pH 8.0. The enzyme 
cleaved APA-pNA 10 times as rapidly as the IL-3 analog, 
APM-pNA. This result agrees with those obtained when com- 
paring the rates of GM-CSF and IL-3 cleavage. The tripeptide 
fl-naphthylamide (bNA), APS-bNA, was also hydrolyzed. 
The elastase substrate, N-Ac-APA-pNA, is completely resis- 
tant to cleavage by TAP. The N-blocked Boc-APS-bNA is not 
hydrolyzed by TAP. The extended N-blocked GM-CSF ana- 
logs, Boc-APARSPA-bNA and N-carbobenzoxy-APARSPA- 
pNA, were not affected by TAP but in a coupled assay the 
reporter groups were rapidly released by simultaneously incu- 
bating the molecules with TAP and TPCK-treated trypsin 
(Sigma). This clearly demonstrates the absolute requirement for 
an unblocked N-terminal group in the substrate. Additionally, 
TAP does not release the reporter group from Boc-AAPA- 
pNA, N-Bz-R-pNA, N-Bz-VGR-pNA, A-pNA, R-pNA, 
L-pNA, P-pNA, S-bNA, AA-pNA, GP-pNA, D-PFR-pNA, or 
AAPA-pNA. The enzyme has shown no abilitity to act on 
monoamino acid, dipeptide, or tetrapeptide substrates. The 
lack of activity towards D-PFR-pNA may result form the 
This resistance may be a function of the primary sequence 
or protection of the cleavage site by the folding of the target 
molecule. IL-3 undergoes a significant shift in pI from 7.4 to 
7.1 upon removal of the APM tripeptide suggesting a structural 
rearrangement or the possible formation of a salt bridge by the 
new N-terminal. 
Crystal structures show the first 14 residues of GM-CSF are 
solvent accessible and the GM-CSF(-3)  form can be further 
degraded by enzymes attacking the N-terminal while NMR 
studies indicate that the N-terminal of IL-6 is also accessible 
[17,18]. It is also possible that the enzyme does not cleave 
tripeptides containing charged residues. EPO(-3) and 
GMCSF( -3)  have arginine as their N-terminal residues 
and appear to resist further cleavage. The resistance of IL-6 
may reside in the primary sequence, Ala-Pro-Val-Pro-Pro. The 
bulky valine side chain may prevent proper alignment in the 
active site. Altematively, the secondary amide may be resistant 
to cleavage. 
Table 1 
Amino acid composition of isolated TAP 
Amino acid Mol percentage 
Asp +Asn 13.6 
Glu + Gin 10.9 
Ser 4.7 
Gly 10.0 
His 2.2 
Arg 7.4 
Thr 6.3 
Ala 14.3 
Pro 7.2 
Tyr 3.9 
Val 6.4 
Met 1.2 
Ile 2.3 
Leu 5.6 
Phe 1.7 
Lys 2.5 
4 3 2 1 st kD 
94.0 
67.0  
43.0 
30.0 
20.1 
14.4  
Fig. 3. SDS-PAGE demonstration f purification of TAP. Approxi- 
mately 20 gg of protein were denatured under educing conditions and 
analyzed by SDS-PAGE on 10% polyacrylamide g ls. St, molecular 
weight standards; lane l, l0 kDa ultrafiltration retentate; lane 2, redis- 
solved pH 4.0 precipitate; lane 3, Q-Sepharose chromatography pool; 
lane 4, PhenyI-Sepharose chromatography pool. 
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Table 2 
Inhibitor survey 
Inhibitor Percentage residual activity 
None 100 
PMSF, 1.6 mM 7 
HgCl2 
0.1 mM 99 
1.0 mM 93 
CaC12 
1.0 mM 96 
l0 mM 97 
COC12 
1.0 mM 98 
10 mM 82 
EDTA 
1.0 mM 95 
10 mM 95 
Iminodiacetic acid 
1.0 mM 82 
10 mM 60 
Ditbiothreitol, 1 mM 86 
Dithiothreitol (1 raM) + 
EDTA (10 raM) 97 
Elastatinal, 0.1 mM 86 
Chymostatin, 0.1 mM 75 
Benzamidine, 10mM 94 
Ampicillin 
1.0 mM 93 
10 mM 94 
N-terminal D-isomer or the presence of the charged arginine as 
discussed above. 
The results of an i hibitor survey are shown in Table 2. The 
enzyme was inhibited by phenylmethanesulfonylfluoride 
(PMSF) suggesting that it is a serine protease. TAP was not 
inhibited or stimulated by chelating agents, divalent cations, or 
sulfhydryl reagents thereby eliminating any relation to the sub- 
tilisins, thiol proteinases, or metalloproteinases. Pepstatin was 
also ineffective. The failure of the peptide aldehydes, elastatinal 
and chymostatin, may reflect TAP's lack of endoproteolytic 
activity. 
The effect of pH on the cleavage of several substrates by TAP 
has been examined. The enzyme was active against APA-pNA 
from pH 5.0 to pH 9.5 with optimal activity at pH 8.0-9.0. Half 
maximal velocities were obtained at pH 7.1 and 9.8. The en- 
zyme cleaved GM-CSF from pH 4.0 to pH 10.0 with a broad 
maximum ranging from pH 5.0 to pH 9.0. The broad maximum 
for GM-CSF probably reflects the extreme s nsitivity of this 
substrate to TAP. As previously mentioned, the GM-CSF crys- 
tal structure shows that the N-terminal ishighly accessible [17]. 
The enzyme also cleaved IL-3 at pH 5.0-9.0 with maximal 
activity at pH 7.0-8.5. 
TAP appears to be a tripeptidyl aminopeptidase capable of 
cleaving substrates at the third amide bond from the N-termi- 
nal. While serine proteases with tripeptidyl aminopeptidase ac-
tivity have been identified in mammals [19-21], enzymes of this 
type have not been reported in prokaryotes. The enzyme is 
similar in size to the lysosomal tripeptidyl aminopeptidases 
isolated from bovine anterior pituitary glands and porcine ova- 
ties but does not exhibit he acidic pH optimum of those serine 
proteases [19,22]. The pH optimum ore closely resembles that 
of the extracellular enzymes from human liver and erythrocytes 
but is considerably smaller than these 135,000 Da enzymes [20]. 
Examination of the TAP DNA sequence may provide some 
insight into evolutionary elationships between the prokaryotic 
and eukaryotic enzymes. 
Bacterial secretion systems for heterologous protein expres- 
sion can be adversely affected by secreted proteases. By isolat- 
ing and characterizing a major protease involved in the degra- 
dation of biopharmaceutical products, the use of Streptomyces 
expression systems can be enhanced by the application f selec- 
tive inhibitors or, ultimately, by the deletion of the protease 
gene from the host genome. 
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